Here’s how we can make clinical trials more inclusive

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Since COVID-19 made its way to the United States, we have seen a stream of worrying news of the pandemic’s impact on cancer care in the U.S., including 9.4 million missed screenings1 for just about all forms of cancer. While screening rates rebounded in the fall of 20202, there’s a growing concern from oncologists that screenings haven’t returned to pre-pandemic levels for everyone. 

And the data are compelling. From September to December 2020, for example, fewer Black and Hispanic women2 had mammograms than in the three months prior to the pandemic. In addition, Black men were 25% less likely3 than their white counterparts to get a prostatectomy during the pandemic. 

There is significant concern among health equity advocates that the pandemic’s ripple effects on cancer care could be sustaining or even deepening widely recognized and reported health disparities for vulnerable communities, including Black, Latinx, and rural Americans.4 Warnings from experts of the pandemic’s impact on cancer disparities necessitate an even greater urgency to further reduce gaps in care.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Jenny Sherak
Senior vice president & President, Specialty Physician Services AmerisourceBergen
Table of Contents

YOU MAY BE INTERESTED IN

The University of Kansas Cancer Center and its outreach network, the Masonic Cancer Alliance, announced a new effort to provide cancer screening throughout the cancer center’s catchment area. Known as HOPE on Wheels: Health, Outreach, Prevention, and Education, a 42-foot bus will help ensure that geography isn’t a barrier to detecting cancers earlier.
Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment. 
The phase III persevERA Breast Cancer study, evaluating investigational giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed. 
Jenny Sherak
Senior vice president & President, Specialty Physician Services AmerisourceBergen

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login